The latest price target for CME Gr (NASDAQ:CME) was reported by Barclays on December 9, 2024. The analyst firm set a price target for $257.00 expecting CME to rise to within 12 months (a possible 7.11% upside). 44 analyst firms have reported ratings in the last year.

The latest analyst rating for CME Gr (NASDAQ:CME) was provided by Barclays, and CME Gr maintained their equal-weight rating.

The last upgrade for CME Group Inc happened on September 6, 2023 when B of A Securities raised their price target to $204. B of A Securities previously had an underperform for CME Group Inc.

The last downgrade for CME Group Inc happened on October 8, 2024 when Redburn Atlantic changed their price target from N/A to $244 for CME Group Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CME Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CME Gr was filed on December 9, 2024 so you should expect the next rating to be made available sometime around December 9, 2025.

While ratings are subjective and will change, the latest CME Gr (CME) rating was a maintained with a price target of $231.00 to $257.00. The current price CME Gr (CME) is trading at is $239.94, which is within the analyst’s predicted range.